nci director’s update · 2019-12-12 · update board of scientific advisors norman e. sharpless,...
TRANSCRIPT
![Page 1: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/1.jpg)
1
NCI Director’sUpdateBoard of Scientific Advisors
Norman E. Sharpless, M.D.
Douglas R. Lowy, M.D.
March 25, 2019
![Page 2: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/2.jpg)
2
By SexAll Races (includes Hispanic), All Ages
Female Male
By Race/EthnicityBoth Sexes, All Ages
Black (includes Hispanic)
White (includes Hispanic)
Source: NCI Surveillance, Epidemiology, and End Results Program
(1975 – 2015)
Long-Term Trends in U.S. Mortality Rates - All Cancer Sites Combined
![Page 3: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/3.jpg)
3
Late-stage pipeline composition by therapeutic area, 2010-18 – original cohort
Clinical cycle time by therapy area(selected therapy areas only), 2016-18
Source: Deloitte Center for Health Solutions, 2018
![Page 4: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/4.jpg)
4From Blumenthal and Pazdur, Nat Rev Clin Oncol, 2019
Cancer drug approvals in 2018
![Page 5: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/5.jpg)
0
5
10
15
20
25
30
2000 2003 2006 2009 2012 2015
Rate
per
100,0
00
Year of diagnosis
Melanoma of the skin
SEER incidence rates
0
0.5
1
1.5
2
2.5
3
2000 2003 2006 2009 2012 2016
Rate
per
100,0
00
Year of death
Melanoma of the skin
US mortality rates
NivolumabCTLA4
Incidence has increased by ~2% per year
2000-2015 Mortality has decreased by ~5% per year
2012-2016
Vemurafenib
Melanoma incidence & mortality
![Page 6: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/6.jpg)
6
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Reaffirm our commitment to basic
science to drive novel approaches and
technologies
B AS I C S C I E N C E
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
![Page 7: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/7.jpg)
7
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
Reaffirm our commitment to basic
science to drive novel approaches
and technologies
B AS I C S C I E N C E
![Page 8: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/8.jpg)
8
Workforce Development
MERITR37
Method to Extend
Research in Time
ESI
PAYLINE
14th
PERCENTILE
![Page 9: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/9.jpg)
9
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
Reaffirm our commitment to basic
science to drive novel approaches
and technologies
B AS I C S C I E N C E
![Page 10: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/10.jpg)
10
FY 2018
RPG POOL
+ $170M over
FY 2017Largest increase
since FY 2003
FY 2019
RPG POOL
˃$100MILLION
![Page 11: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/11.jpg)
11
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Reaffirm our commitment to basic
science to drive novel approaches and
technologies
B AS I C S C I E N C E
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
![Page 12: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/12.jpg)
12
Modernizing Clinical Trials
January 23, 2019
![Page 13: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/13.jpg)
13
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Reaffirm our commitment to basic
science to drive novel approaches and
technologies
B AS I C S C I E N C E
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
![Page 14: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/14.jpg)
14
Childhood Cancer Data Initiative
• Data infrastructure
and inter-operability
• Data acquisition
• Extramural grants
![Page 15: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/15.jpg)
15
Key Focus Areas
Fully realize the power of clinical trials
through innovative design,
administration, and analyses
C L I N I C AL T R I AL S
Support the cancer research enterprise
by focusing on the workforce of cancer
investigators
W O R K F O R C E D E V E L O P M E N T
Reaffirm our commitment to basic
science to drive novel approaches and
technologies
B AS I C S C I E N C E
Increase data aggregation and
interpretation to speed our work across
the cancer enterprise
B I G D ATA
![Page 16: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/16.jpg)
16
Cancer Moonshot Funding Authorized Under the 21st Century Cures Act (dollars in millions)
300 300
400
195 195 194 216
00
50
100
150
200
250
300
350
400
450
FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024
![Page 17: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/17.jpg)
17
21st Century Cures Act
funding shown in orange
$4,950$5,215
$5,389$5,665 $5,744
$5,055
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000
FY 2015 FY 2016 FY 2017 FY 2018 FY 2019 President’s 2020 Budget Proposal
$5,689$300
$300
$5,965$400
$6,144
NCI Appropriations FY 2013 - 2019 (in millions)
$5,250
$195
![Page 18: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/18.jpg)
18
NCI/NIH BUDGET PROCESS FOR REGULAR APPROPRIATION
White House OMB
coordinates with
federal agencies
to formulate the
President’s budget
proposal
Congressional
appropriations
committees
consider
President’s
proposal &
prepare legislation
Congress
reconciles &
finalizes
appropriations
legislation & sends
to the President
President signs
the appropriations
bill into law
making funds
available for
NIH & NCI
STEP 1 STEP 2 STEP 3 STEP 4
FY 2019
FY 2020
![Page 19: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/19.jpg)
19
• Director, Center for Global Health (CGH)
• Director, Center for Bioinformatics and Information
Technology (CBIIT)
• Director, Cancer Therapy Evaluation Program
(CTEP)
• Director, Division of Cancer Prevention (DCP)
Leadership transitions
![Page 20: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/20.jpg)
20
Associate Director, NCI at Frederick
• Cancer Research Technology Program, Frederick
National Laboratory for Cancer Research
• NCI’s Office of Cancer Nanotechnology Research
• Research Associate, University of Virginia Health
Sciences Center, Department of Biochemistry and
Molecular Genetics
• Post-doctoral Fellowship, Fred Hutchinson Cancer
Research Center, Division of Basic Sciences
• Ph.D. in Pharmacology, Duke University Medical
Center in 1999Sara Hook, Ph.D.
![Page 21: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/21.jpg)
21
NCI @ AACR 2019
• 15 NCI-sponsored sessions
• > 25 additional
presentations by NCI staff
• 40 Meet-the-Experts
sessions at the NCI Exhibit
• 80 poster sessionsOpening
Ceremony
Sunday, March 31
9:00 AM
![Page 22: NCI Director’s Update · 2019-12-12 · Update Board of Scientific Advisors Norman E. Sharpless, M.D. Douglas R. Lowy ... White (includes Hispanic) Source: NCI Surveillance, Epidemiology,](https://reader034.vdocument.in/reader034/viewer/2022042403/5f16e7bbbdae6e493b42d288/html5/thumbnails/22.jpg)
www.cancer.gov
www.cancer.gov/espanol